Abstract Bacterial infection is the primary initiator and driver of inflammation and lung injury in the airways of people with cystic fibrosis. Infection begins early in life and over time becomes chronic in many patients. Pseudomonas aeruginosa is the dominant pathogen in chronic infection and is associated with an accelerated decline in lung function, more frequent exacerbations, and reduced survival compared to people with no Gram-negative infection. Antibiotic eradication therapy is effective in delaying chronic infection with P. aeruginosa and can be employed repeatedly to new infections. When chronic infection develops, long-term inhaled antibiotics and azithromycin therapies reduce exacerbations, improve QoL, and may impact survival. Pulmonary exacerbations driven by infection and inflammation are associated with decline in lung function and reduced survival. Optimal therapy for these requires multiple antibiotics and close assessment of response. A number of other bacteria such as Staphylococcus aureus, Stenotrophomonas maltophilia, Achromobacter spp. and nontuberculous mycobacteria are an increasing problem in CF infection and bring new challenges to therapy.
Introduction
Cystic fibrosis remains the most common life-shortening autosomal recessive disorder in Western European communities. CF is not exclusive to Western Europeans, but occurs at a significantly higher prevalence among white than in African and Asian populations. It is estimated that there are around 30,000 people with cystic fibrosis in the USA and around 35 ,000 in Europe [1] . Over 2,000 autosomal recessive mutations have been described of the cystic fibrosis transmembrane regulator protein. Many of these are private mutations occurring in single families, and for some it is not clear if they are disease-causing. A recent major effort by a group in Johns Hopkins has produced a robust online database of mutations based on international registry data on mutations that are disease causing and the associated phenotypes [2] .
Cystic fibrosis disease is caused by a dysfunctional cystic fibrosis transmembrane regulator protein which is primarily a chloride ion channel expressed in epithelial cells [3] . The primary action of this channel is chloride ion transport, but it also negatively controls sodium transport through the epithelial sodium channel (ENaC). The CFTR and ENaC channels control the hydration of airway surface liquid which is key to mucociliary clearance [4, 5 •• ] . CFTR is also a bicarbonate transporter and may be important in regulating the pH of airway surface liquid and directly affect the function of innate immune peptides [6 •• ] .
People with cystic fibrosis generally develop infection early in life [7] . This is associated with a neutrophil-mediated inflammatory response which is partially effective in phagocytosing bacteria [8 •• , 9] . However, with repeated episodes of infection in the milieu of reduced mucociliary clearance, bacteria have the opportunity to proliferate and form biofilms, and inflammation in the airway becomes chronic and self-enduring [10] . Proteases and oxidants are released from neutrophils which are frustrated as they cannot phagocytose bacteria protected by biofilms. These proteases and oxygen radicals impair innate immune system functions, further impairing phagocytosis [9] . The major airways, small bronchi and alveoli are damaged in this process, resulting in airway wall thickening and bronchiectasis with dilation of medium and small airways [8 •• ] . These proteases also damage alveolar tissue and result in destruction of gas exchanging membranes.
Some studies have suggested that epithelial and possibly immune cells in cystic fibrosis have an augmented inflammatory response to pathogens. This is not entirely determined, and while this might be important in early infection, in established infection there is such a high load of bacteria that this is unlikely to be a major factor.
Bacteriology of Cystic Fibrosis
The bacteria isolated from airways secretions from people with cystic fibrosis (Fig. 1) come from several distinct genera. Early in life Staphylococcus aureus, either methocilliin resistant (MRSA) or sensitive (MSSA), dominate the flora, however Haemophilus influenzae, Stenotrophomonas maltophilia and a range of other Gram-negative bacteria can also cause infection. Into the second decade, Pseudomonas aeruginosa becomes established as a chronic infection in many young people. This is now aggressively treated with eradication therapy and the prevalence of Pseudomonas in children is steadily reducing [12 •• ] . Many CF centres now have a prevalence of less than 10 % of those under 18 with chronic P. aeruginosa infection. Other troublesome Gram-negative bacteria also play an important role. Bacteria from the Burkholderia cepacia complex, most particularly Burkholderia cenocepacia, Burkholderia multivorans and Burkholderia dolosa have all been associated with outbreaks [13] . These organisms are associated with constitutive resistance to most antimicrobial agents, have increased virulence, and in the case or B. cenocepacia or B. dolosa, are associated with reduced survival [14] . Other Burkholderia species such as B. gladiolii can also cause airway infection. Achromobacter are an increasing challenge in the CF airway and may be an opportunist pathogen in patients who have had a lot of antibiotic therapy. It was thought until recently that Achromobacter xyloxidans was the infecting agent in the majority of patients but recent genomic studies have indicated that a wide range of species are involved [15, 16] . S. maltophilia is also constitutively resistant to many antibiotics and is associated with generally poor outcomes, and present significant challenges in terms of treatment [17] .
The Airway Microbiome in Cystic Fibrosis
The appreciation that microbes are present in many niches in the healthy human body has been driven by application of molecular approaches to the identification of microorganisms [18] . In cystic fibrosis, genomic approaches using terminal restriction fragment length polymorphism (T-RFLP) to explore bacterial population diversity, and more recently pyrosequencing, indicate that the airways microbiology is highly complex. Such complexity presents many new challenges in terms of how treatment is considered. Studies have demonstrated that in many patients over 100 different taxa can be identified using pyrosequencing approaches indicating a significant diversity of bacteria [19, 20] . A surprising number of bacteria identified in these studies are anaerobes which are present in significant numbers by culture and pyrosequencing methods. The common genera in these studies identified are Prevotella, Veilonella, Gemella and Rothia species [21, 22] . These bacteria are common in the upper airways but often not in the high numbers identified in sputum. The relationship of this diverse microbiota and the dominant infecting organisms such as S. aureus, P. aeruginosa and B. cepacia complex organisms is still unclear. However it is highly likely that these organisms interact through quorum sensing mechanisms and may modify virulence, inflammation and susceptibility to antibiotics.
Dominant Pathogens
There has been interesting new data on infection with S. aureus published in the last 5 years [23, 24] . It is now agreed that prophylactic antistaphylococcal antibiotic therapy is ineffective, and there are significant concerns that it may promote earlier infection with P. aeruginosa [24] . Methicillin resistant S. aureus (MRSA) is becoming an increasing challenge in paediatric centres [23] . The prevalence of this organism can be as high as 35 % and represents cross infection and therapeutic challenges in both infection control and therapy. MRSA organisms found in the sputum of people with CF usually reflect the common MRSA organisms prevalent in local institutions.
It has also become evident that P. aeruginosa is an orgnaism highly adapted to the niche of the airways in CF. Under stressful conditions found in the CF airway, Pseudomonas evolves a range of genetic and phenotypic changes that allow it to adapt and prosper in the CF airways [10] . This includes considerable diversity in the ability to develop antimicrobial resistance. A shift to increased expression of genes in the algU regulon results in downregulation of metabolism, motility and virulence and upregulation of genes controlling membrane permeability and efflux [10] . The frequent use of antibiotics is a further driver of resistance.
Infection Control
Patient to patient transmission of bacteria in cystic fibrosis has been a major area of concern since the late 1980s, when the first outbreak of infection with what we now know to be B. cenocepacia occurred in Canada [25] . This organism is likely to have been transmitted during summer camps which were encouraged at that time to help increase the confidence and independence of young people with cystic fibrosis. These camps were attended by people with CF from the UK and Ireland and may have been the source for index cases in CF centres in the British Isles [26] [27] [28] . A number of important studies demonstrated the clonality of this organism and its ability to spread from patient to patient. In the case of B. cenocepacia, transmissibility is associated with virulence, which in many patients is rapidly lethal. The appreciation of this in the 1990s has resulted in very stringent infection control in CF centres throughout the world [29] .
It is also clear that some strains of P. aeruginosa are also transmissible [30, 31] . Important studies in Europe and Australia have identified clonal strains, and it is likely that there has been patient to patient transmission [32] . The association with virulence is much less clear with transmissible strains of Pseudomonas. No study has definitively demonstrated a reduction in survival, though some studies suggest an increased morbidity with pulmonary exacerbations and hospital admissions. Most recently, two studies have suggested that Mycobacterium abscessus, particularly the subspecies M. massiliense, can be spread from patient to patient [33, 34 •• ] . Nontuberculous mycobacterial infection, particularly with M. abscessus complex strain, is becoming more common in the cystic fibrosis population, and this study adds further concerns about infection control as it occurred in a centre with excellent infection control aimed at preventing transmission of P. aeruginosa and other Gram-negative bacteria [34
It is clear from the above that infection control needs to be considered in all CF centres and this optimally requires no contact between patients with private rooms during hospital admission, and appropriate arrangements for outpatient clinics to minimise patient to patient contact. Meticulous infection control measures, including hand hygiene and proper cleansing of equipment (including lung function machines and stethoscopes in the outpatient setting), are also important. Infection control issues can be very problematic within families when one sibling with cystic fibrosis acquires, for example, B. cenocepacia or B. multivorans infection and has another sibling with CF who does not have this organism. This can result in considerable social and emotional challenges for families.
Microbial Surveillance and Diagnosis
The accurate identification of bacteria in the sputum of people with cystic fibrosis is critically important. This is primarily to ensure that appropriate antibiotics are used to treat infection in the airways and secondly to provide surveillance for new organisms and potentially cross infection. Where possible, sputum samples are taken at regular outpatient and inpatient hospital attendances. When sputum is not available, which is increasingly common with children with good lung function, cough swabs can be used though these are of less value than sputum [35] . The sputum cough swabs, or in some cases bronchiolar lavage, needs to be carefully cultured with appropriate selective media to enable the identification of the appropriate range of organisms [35] . The identification of bacteria is usually undertaken through an automated biochemical testing system such as Vitek or API20NE, but these systems are not entirely accurate particularly for less common Gram-negative species. Susceptibility testing should be undertaken for all the common species. This is helpful in determining the appropriate antibiotic to use in many cases. However, there is evidence to suggest that once chronic P. aeruginosa infection has become established in the airways that antimicrobial sensitivity testing is unhelpful and in some cases inaccurate [12 •• , 36, 37] . Synergy testing to determine optimal antibiotic choice has also been shown not to be of benefit and does not appear to affect the prescription of antibiotics or the outcome of treatment [38] .
Antibiotic Treatment for Cystic Fibrosis

Staphylococcus aureus
For some time there has been debate around using prophylactic anti-staphylococcal therapy, particularly in children with cystic fibrosis [39] . There is no definitive study yet to support this. A recent meta-analysis of studies there is a suggestion that long-term prophylaxis is associated with higher isolation rate of P. aeruginosa [39] . This practice is still employed in a few countries, but in general prophylactic therapy is not used. Treatment of S. aureus is straightforward when it is sensitive to flucloxacillin or methicillin, when conventional semisynthetic antistaphylococcal penicillins (flucloxacillin, oxacillin, nafcillin) can be used. However, MRSA has become an increasingly prevalent infection in CF Centres. A positive culture of MRSA is associated with lower lung function and higher rates of hospital admission and antibiotic usage [40] . There has also been an association with an increased mortality demonstrated from a registry study [23] . There is a growing consensus that MRSA should be eradicated. and there are a number of current and proposed clinical trials which are attempting to determine the most effective regime. A small case series using rifampicin, fusidic acid, vancomycin, vibramycin, co-trimoxazole and linezolid, usually in a combination of two drugs, have demonstrated eradication, but it is not clear which of these is most effective.
Haemophilus influenzae
Haemophilus influenzae is a reasonably common isolate particularly in children and teenagers with CF and may be co-cultured with other bacteria. It is usually sensitive to amoxicillin/clavulanate and doxycycline which are appropriate antibiotics for this organism [12 •• ] .
Pseudomonas aeruginosa
Pseudomonas aeruginosa represents the most difficult and challenging bacteria in the CF airways and accounts for a considerable amount of the morbidity and may also drive decrease in lung function and associated reduction in survival [12 •• ] . Antibiotic treatment directed against P. aeruginosa can be considered in three specific areas: antibiotic eradication therapy (AET), treatment of pulmonary exacerbations and treatment of chronic P. aeruginosa infection.
Antibiotic Eradication Therapy
There is a very compelling rationale for antibiotic eradication therapy in people infected with P. aeruginosa for the first time or intermittently following previous successful eradication treatments. This was first described using a combination of inhaled colistin and oral ciprofloxacin, but subsequently has also been shown to be efficacious with inhaled tobramycin alone [40, 41] . Two small studies have compared these respective regimes and not identified any significant difference in the eradication rate [42, 43] . We have no data yet to determine if eradication of P. aeruginosa improves lung function and survival. However, it is highly likely that postponing chronic infection with P. aeruginosa for as long as possible is likely to be helpful in improving both of these outcomes. With repeated episodes of eradication therapy it is likely there will be more failures to eradicate, and a recent consensus conference has suggested an algorithm to maximise the success of antibiotic eradication therapy (AET) (Fig. 2) .
Treatment of Chronic P. aeruginosa Infection
The majority of people with cystic fibrosis still have chronic infection with P. aeruginosa. Long-term treatment with inhaled antibiotics has been demonstrated to improve pulmonary function and quality of life and to increase the time between and thus decrease the frequency of pulmonary exacerbations [12 •• , 44] . Tobramycin and colistin have both been licensed for this purpose for some time, though the data for tobramycin is considerably more compelling than for olistin [45] . Recently aztreonam lysine has been approved and has shown noninferiority to alternate tobramycin. One of the challenges with inhaled antibiotic therapy is that tobramycin is licensed to be used on alternate months to reduce the development of resistance. However, on the off month many patients have more symptoms, and increasingly this off month is being filled with either treatment with colistin or aztreonam. It is not clear what might be the most effective cycling therapy for CF. Tobramyin and colistin are now both available as dry powder inhalers, which is likely to be helpful in terms of adherence as these require less time than nebulised therapy [46, 47] . Levofloxacin, ciprofloxacin and amikacin are all being developed as new antibiotics for use in cystic fibrosis [48] [49] [50] [51] [52] [53] .
Exacerbations in People with Chronic Pseudomonas Infection
Pulmonary exacerbations are very important events in people with cystic fibrosis [54] . Exacerbations are associated with an increase in symptoms and systemic markers of inflammation and often a reduction in lung function [55] [56] [57] . Pulmonary exacerbations are associated with accelerated declines in lung function and a number of recent studies also suggest they are associated with reduced survival. Preventing these pulmonary exacerbations is of utmost importance. This can be achieved by combinations of mucolytic therapies such as Dornase alpha and hypertonic saline, inhaled antibiotics as discussed above and regular macrolide therapy using azithromycin [45] . Azithromycin is thought to have a combination of antimicrobial and anti-inflammatory effects. However, despite these therapies which have good evidence from randomised controlled trials that they prevent exacerbations, many people with Pseudomonas have exacerbations [45] .
Treating exacerbations with the appropriate antibiotics in addition to supportive therapy with increased airways clearance is critically important as up to a quarter of patients can fail to recover their lung function following these episodes. Antibiotic therapy is determined somewhat empirically although in vitro antimicrobial testing can be of some general value. However a number of small studies have suggested that knowing the resistance to bacteria does not improve outcomes [12 •• ] . Intravenous antibiotic therapy can be successfully delivered in hospital and at home. There have been few efficacy or economic evaluations comparing these approaches [12 •• ] . However, it is critically important that supportive therapy such as increased airways clearance, nutrition, and social support are provided for both hospital and home delivery of intravenous antibiotics. The duration of intravenous therapy is usually 10-14 days and persisting beyond 21 days with the same antibiotics is not recommended [12 •• ] .
Antibiotic Treatment for Other Bacterial Pathogens
A range of other Gram-negative bacteria are problematic in people with CF. There are a few case reports that these organisms can be eradicated although there is little consensus about what appropriate regimes should be used. Exacerbations are empirically using anti-pseudomonal antibiotic usually combined with tetracycline, co-trimoxazole and in the case of B. cepacia complex chloramphenicol [17, 58] . Detailed guidelines for these organisms are available in the Cystic Fibrosis Trust Antibiotic Guidelines [58] . Treatment of nontuberculous mycobacteria (NTM) is also very challenging and based on American Thoracic Society Guidelines [59] . Recently, streptococci which are found in high numbers in CF sputum have been associated with pulmonary exacerbations and in some instances it may be helpful to treat [60] .
Resistance, Toxicity and Allergy
Antimicrobial resistance is common in CF organisms and is of concern. This is particularly important, as people with cystic fibrosis born now are likely to live into their 50s and 60s and have an enormous lifetime exposure to antibiotics. Strategies to ensure effective treatment while minimising resistance need to be considered [58] . Antibiotics can also have accumulative toxicity in CF, in particular the aminoglycosides have been associated with nephrotoxicity [61] . This is particularly an issue with gentamicin but accumulative doses of other aminoglycosides can impair renal function. Antibiotic allergy is also common in cystic fibrosis and does not easily fit into the classic definition. Desensitisation can be undertaken successfully [62] .
Conclusion
The use of antimicrobial agents in the treatment of cystic fibrosis has been a key part of the improved outcomes in this condition. Understanding the complexity of airways infection and developing more effective approaches to treatment is still a very important aspect of CF care.
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